Influenza Update N° 418

2 May 2022
 | Emergency situation update
Influenza Update N° 418
Download (1.2 MB)

Overview

02 May 2022, based on data up to 17 April 2022

Information in this report is categorized by influenza transmission zones, which are geographical groups of countries, areas or territories with similar influenza transmission patterns. For more information on influenza transmission zones, see the link below:

Influenza Transmission Zones (pdf, 659kb)

  • The current influenza surveillance data should be interpreted with caution as the ongoing COVID-19 pandemic has influenced to varying extents health seeking behaviours, staffing/routines in sentinel sites, as well as testing priorities and capacities in Member States. Various hygiene and physical distancing measures implemented by Member States to reduce SARS-CoV-2 virus transmission have likely played a role in reducing influenza virus transmission.
  • Globally, influenza activity remained low, with a further decrease of activity in some areas.
  • With the increasing detections of influenza during COVID-19 pandemic, countries are recommended to prepare for co-circulation of influenza and SARS-CoV-2 viruses. They are encouraged to enhance integrated surveillance to monitor influenza and SARS-CoV-2 at the same time, and step-up their influenza vaccination campaign to prevent severe disease and hospitalizations associated with influenza. Clinicians should consider influenza in differential diagnosis especially for high-risk groups for influenza, and test and treat according to national guidance.
  • In the temperate zones of the northern hemisphere, influenza activity seems to decrease except in North America. Detections were mainly influenza A(H3N2) viruses and B/Victoria lineage viruses.
  • In North America, influenza activity continued to increase in recent weeks but remained lower than pre-COVID-19 pandemic levels at this time of the year and was predominantly due to influenza A viruses, with A(H3N2) predominant among the subtyped viruses. Respiratory syncytial virus (RSV) activity remained low in the United States of America (USA) and Canada. 
  • In Europe, overall influenza activity appeared to decline, with influenza A(H3N2) predominant. 
  • In Central Asia, sporadic influenza B detections were reported in Kazakhstan.
  • In East Asia, influenza activity with mainly influenza B/Victoria lineage detections continued to decrease in China. ILI rate and pneumonia hospitalizations remained elevated in Mongolia. Elsewhere, influenza illness indicators and activity remained low. 
  • In Northern Africa, decreased detections of influenza A(H3N2) were reported in Tunisia. 
  • In Western Asia, Georgia reported increased detections of influenza A(H3N2).
  • In the Caribbean and Central American countries, low influenza activity was reported with influenza A(H3N2) predominant.
  • In tropical South America, low influenza activity was reported with influenza A(H3N2) predominant.
  • In tropical Africa, influenza activity was reported mainly from Eastern Africa with influenza A(H3N2) predominating followed by influenza B viruses.
  • In Southern Asia, influenza virus detections were at low levels overall. 
  • In South-East Asia, only Malaysia reported influenza detections of influenza A(H3N2) and B viruses.
  • In the temperate zones of the southern hemisphere, influenza activity remained low overall, although detections of influenza A viruses, predominant with A(H3N2), continued to be reported in some countries in temperate South America and South Africa.
  • National Influenza Centres (NICs) and other national influenza laboratories from 112 countries, areas or territories reported data to FluNet for the time period from 04 April 2022 to 17 April 2022* (data as of 2022-04-29 06:59:32 UTC). The WHO GISRS laboratories tested more than 336 269 specimens during that time period. 33 676 were positive for influenza viruses, of which 33 139 (98.4%) were typed as influenza A and 537 (1.6%) as influenza B. Of the sub-typed influenza A viruses, 533 (9.5%) were influenza A(H1N1)pdm09 and 5 085 (90.5%) were influenza A(H3N2). Of the characterized B viruses, 337 (100%) belonged to the B-Victoria lineage.

During the COVID-19 pandemic, WHO encourages countries, especially those that have received the multiplex influenza and SARS-CoV-2 reagent kits from GISRS, to conduct integrated surveillance of influenza and SARS-CoV-2 and report epidemiological and laboratory information in a timely manner to established regional and global platforms. Revised interim guidance has just been published here: https://covid.comesa.int/publications/i/item/WHO-2019-nCoV-integrated_sentinel_surveillance-2022.1.

  • At the global level, SARS-CoV-2 percent positivity from sentinel surveillance decreased below 10% in all WHO regions during this reporting period. Overall positivity from non-sentinel sites also showed a decreasing trend.
  • NICs and other national influenza laboratories from 53 countries, areas or territories from five WHO regions (Region of the Americas: 16; Eastern Mediterranean Region: 4; European Region: 27; South-East Asia Region: 3; Western Pacific Region: 3) reported to FluNet from sentinel surveillance sites for time period from 04 Apr 2022 to 17 Apr 2022 (data as of 2022-04-29 06:59:33 UTC). The WHO GISRS laboratories tested more than 30 300 sentinel specimens during that time period and 2 290 (7.6%) were positive for SARS-CoV-2. Additionally, more than 547 099 non-sentinel or undefined reporting source samples were tested in the same period and 30 704 were positive for SARS-CoV-2. Further details are included at the end of this update and in the surveillance outputs.

Source of data

______________________________________________________________________________________________

The Global Influenza Programme monitors influenza activity worldwide and publishes an update every two weeks. The updates are based on available epidemiological and virological data sources, including FluNet (reported by the WHO Global Influenza Surveillance and Response System), FluID (epidemiological data reported by national focal points) and influenza reports from WHO Regional Offices and Member States. Completeness can vary among updates due to availability and quality of data available at the time when the update is developed.

*It includes data only from countries reporting on positive and negative influenza specimens.

 

WHO Team
Global Influenza Programme (GIP)